Cool results, mostly expected to be honest. The BIG unanswered question is; what next?:
- will big pharma bite on a ph3 NSCLC trial? or does management run their own ph3?
- why hasnt management addressed the impact of ADC drugs on future AIPAC trial?
- when can we expect initial Tacti-003 data?
Ann: TACTI-002 data presented at SITC for Efti in 1st line NSCLC, page-2
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.005(1.72%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 29.8¢ | 29.0¢ | $539.5K | 1.834M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 214062 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 469318 | 5 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |